2023 Young Investigator Meeting Agenda

This agenda has been prepared to provide information regarding the upcoming meeting and is subject to change.

Main Menu

8:00 AM

Welcome and Introductions

Welcome & Opening Remarks by Jennifer R. Brown, MD, PhD & Co-Chairs Elisa ten Hacken, PhD, Philip Thompson, BA, BSW, MSW, PhD

Session 1: Pathogenesis of CLL – Session Chairs: Elisa ten Hacken, PhD & Basile Stamatopoulos, PhD

8:10 AM

Oral Presentation

LYN kinase and its regulator CSK as key players in CLL-supporting macrophages

Presenting Author: Viktoria Kohlhas

8:20 AM

Oral Presentation

PI3K inhibitor-resistant B-cell lymphomas show distinct functional phenotypes characterized by sensitivity to Bcl-2- or proteasome-inhibition

Presenting Author: Johanne Hermansen, MSc

8:30 AM

Oral Presentation

The RNA-binding protein Musashi2 is regulated by NOTCH1/KLF4 pathway and support tumor survival keeping CLL cells in proliferative niches during disease progression

Presenting Author: Juliana Querol Rivas

8:40 AM

Oral Presentation

ZMYM3 Mutations Dysregulate Histone Acetylation and Impact the Outcome Of Chronic Lymphocytic Leukemia Patients

Presenting Author: Alberto Rodríguez Sánchez, BSc

8:50 AM

Oral Poster

Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL

Presenting Author: Mercedes Borge, PhD

8:55 AM

Oral Poster

m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia

Presenting Author: Hui Jin, MD

9:00 AM

Oral Poster

Refining the phenotypic and functional intraclonal complexity in chronic lymphocytic leukemia B cells uncovers a discrepancy between surface membrane IG levels and time since birth supporting the requirement for multifactorial activation and different subclonal sensitivities to treatment.

Presenting Author: Andrea Mazzarello, PhD

9:05 AM

Oral Poster

Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL

Presenting Author: Marek Mraz, MD, PhD

9:10 AM

Session Panel Discussion

9:20 AM

BREAK

Session 2: Translational Research of CAR T-Cells – Session Chair: William Wierda, MD, PhD

9:35 AM

Oral Presentation

Combining CD19 CAR T cells with T cell-engaging bispecific antibody treatment enhances efficacy in murine models of CLL and ex vivo patient cultures

Presenting Author: Alessia Floerchinger, MSc

9:45 AM

Oral Presentation

Expression of SIGLEC-10 ligands CD24 and CD52 limit T cell and CAR-T cell function in CLL

Presenting Author: Fleur S. Peters, PhD

9:55 AM

Oral Presentation

Generation and preclinical evaluation of a novel ROR1-specific CAR T-cells against chronic lymphocytic leukemia

Presenting Author: Md Kamrul Hasan, PhD

10:05 AM

Session Panel Discussion

10:15 AM

BREAK

Session 3: Translational Research in CLL – Session Chairs: Fleur Peters, PhD & Marek Mraz, MD, PhD

10:25 AM

Oral Presentation

Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL

Presenting Author: Ana Colado, PhD

10:35 AM

Oral Presentation

NX-2127 and NX-5948, two clinical stage cereblon-recruiting BTK degraders, facilitate T-cell functionality in CLL

Presenting Author: Tiana Huynh

10:45 AM

Oral Presentation

Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244

Presenting Author: Daisy Diaz Rohena, BS

10:55 AM

Oral Presentation

T-cell Transcriptional and Mitochondrial Fitness Reprogramming in CLL Using PI3Kδ Inhibitors

Presenting Author: Wael Gamal, MSc

11:05 AM

Oral Poster

Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genome-wide CRISPR screening

Presenting Author: Lenka Dostálová, MSc

11:10 AM

Oral Poster

Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance

Presenting Author: Huayuan Zhu, MD

11:15 AM

Oral Poster

Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients

Presenting Author: Huayuan Zhu, MD

11:20 AM

Oral Poster

T cell type abundance and gene expression patterns in the context of clinical progression of treatment-naïve CLL/MBL patients from the OxPLoreD study

Presenting Author: Grigore-Aristide Gafencu, BMBS, DPhil

11:25 AM

Oral Poster

The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia

Presenting Author: Britten Gordon, BS

11:30 AM

Oral Poster

Toll-like receptor 9 signalling in CLL: a resistance mechanism to B-cell receptor-targeted treatments, and a potential tool for therapeutic stratification.

Presenting Author: Emma Kennedy, PhD

11:35 AM

Oral Poster

XPO1 mutations identify early stage CLL characterized by shorter time to first treatment and enhanced BCR signaling

Presenting Author: Riccardo Moia, MD

11:40 AM

Session Panel Discussion

11:50 AM

LUNCH BREAK

Session 4: Approach Considerations and Treatment Options in CLL – Session Chairs: Kerry Rogers, MD & Philip Thompson, BA, BSW, MSW, PhD

12:30 PM

Oral Presentation

A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)

Presenting Author: Mazie Tsang, MD, MAS, MS

12:40 PM

Oral Presentation

Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens

Presenting Author: Paul Hampel, MD

12:50 PM

Oral Presentation

Explainable Machine Learning to Identify Chronic Lymphocytic Leukemia Based on Gut Microbiome Data

Presenting Author: Carsten Niemann, MD, PhD

1:00 PM

Oral Presentation

Mutations and translocations associated with venetoclax resistance in chronic lymphocytic leukemia (CLL)

Presenting Author: Kiyomi Mashima, MD, PhD

1:10 PM

Oral Presentation

Sensitive monitoring of sequential targeted therapy resistance in relapsed/therapy refractory chronic lymphocytic leukemia

Presenting Author: Lili Kotmayer, MD, PhD

1:20 PM

Oral Presentation

Single center report on cohort of patients relapsed on Bruton Tyrosine Kinase inhibitors (BTKi)

Presenting Author: Huayuan Zhu, MD

1:30 PM

Oral Presentation

Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon

Presenting Author: Thomas Lew, MBBS

1:40 PM

Oral Poster

Association between hypertension and overall survival in chronic lymphocytic leukemia

Presenting Author: Noomi Vainer, MD

1:45 PM

Oral Poster

Changes in immune cell numbers and profile during long-term zanubrutinib treatment in treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia

Presenting Author: Maria Andersson, MD

1:50 PM

Oral Poster

Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.

Presenting Author: Francesco Autore, MD, PhD

1:55 PM

Session Panel Discussion

2:05 PM

BREAK

Keynote and YIM Award Presentations – Session Chairs: Elisa ten Hacken, PhD & Basile Stamatopoulos, PhD

2:20 PM

Keynote Presentation: Anna Schuh, MD, PhD

2:50 PM

Awards / Concluding Remarks

3:05 PM

Adjourn